AgomAb Therapeutics N.V. American Depositary Shares
NASDAQ:AGMBBiotechnology
+$0.25 today
- Market cap
- $286.62M
- Beta
- 2.62
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$1.28
Volume 0.13M
Average 0.14M
AGMB Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
AgomAb Therapeutics N.V. American Depositary SharesNASDAQ: AGMB
Operating Expenses · Q4 FY2024 · quarter ended Dec 2024
Operating expenses of €11.81M in Q4 FY2024
Q4 FY2024 operating expenses was €11.81M.
Context
- Operating expenses increased in 2 of the last 2 fiscal years.
- FY2024 was the highest annual figure in the 3 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
EUR · from the income statement
- Latest · FY2024
- 48.02M EUR
- Year-over-year change
- +54.0%
- 2-year CAGR
- +45.7%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2024 | 2024-12-31 | 48.02M | +54.0% |
| FY2023 | 2023-12-31 | 31.19M | +37.8% |
| FY2022 | 2022-12-31 | 22.63M | — |
Operating Expenses vs competitors
How AGMB compares with its peers on the latest reported figures
- Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +54.0% is the 2nd highest of 5, against a peer median of -19.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $465.53M USD | +1.6% | +58.0% | 6292.6% |
| LTM Mar 2026 | $229.74M USD | +420.0% | +71.3% | 98.9% | |
| LTM Mar 2026 | $86.87M USD | -40.0% | -8.6% | 1038.2% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | FY2024 | €48.02M EUR | +54.0% | — | — |
| LTM Mar 2026 | $20.3M USD | -54.6% | -32.8% | — | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding AGMB) | — | -19.2% | +24.7% | 1038.2% | |
Competitors are the stored peer set for AGMB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 |
| Gross Margin | — | — | — |
| Research & Development | 19.42M | 26.31M | 39.31M |
| Selling, General & Admin | 4.49M | 6M | 9.82M |
| Operating Expenses | 22.63M | 31.19M | 48.02M |
| Depreciation & Amortization | 23K | 99K | 311K |
| EBITDA | (10.74M) | (11.88M) | (45.89M) |
| EBITDA Margin | — | — | — |
| Operating Income | (22.63M) | (31.19M) | (48.02M) |
| Operating Margin | — | — | — |
| Interest Income | 71K | 245K | 1.22M |
| Interest Expense | 45K | 31K | 67K |
| Other Income / Expenses | 11.83M | 19.18M | 1.76M |
| Income Before Tax | (10.81M) | (12.01M) | (46.26M) |
| Pre-Tax Margin | — | — | — |
| Income Tax Expense | (2.66M) | (619K) | 4K |
| Net Income | (8.14M) | (11.39M) | (46.27M) |
| Net Margin | — | — | — |
| EPS (Basic) | (0.22) | (0.31) | (1.26) |
| EPS (Diluted) | (0.22) | (0.31) | (1.26) |
| Weighted Avg Shares | 36.24M | 36.24M | 36.24M |
| Weighted Avg Shares (Diluted) | 36.24M | 36.24M | 36.24M |
AgomAb Therapeutics N.V. American Depositary Shares
NASDAQ:AGMB
Intrinsic Alpha fair value
Locked
Current Price
$5.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.